CervoMed Inc. announced it will present updates on its neflamapimod clinical program for Lewy body dementia, including new MRI analyses from a Phase 2b trial, regulatory alignment, and a finalized Phase 3 trial design, at an industry meeting on April 7, 2026.
Key takeaways
CervoMed will present neflamapimod clinical program updates at the 2026 Lewy Body Dementia Association Annual Meeting on April 7, 2026.
The update includes new MRI analyses from the Phase 2b RewinD-LB trial showing potential reduction of basal forebrain atrophy in DLB patients.
The company has aligned with global regulatory authorities on the planned Phase 3 trial design for neflamapimod in DLB.
CervoMed plans to initiate a global Phase 3 trial in DLB patients without Alzheimer's disease co-pathology in the second half of 2026, subject to funding.
Additional MRI analysis data will be presented at the 2026 American Academy of Neurology Annual Meeting on April 22, 2026.
Neflamapimod is an investigational oral drug targeting neuroinflammation and synaptic dysfunction in degenerative brain disorders.